Rocket Pharmaceuticals Inc (RCKT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 331.93 is considered Undervalued compared with the five-year average of -6.90. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 69.21 to 73.86 according to relative valuation method. Compared to the current price of 4.99 USD , Rocket Pharmaceuticals Inc By Undervalued By 92.79%.

Relative Value

Fair Zone

69.21-73.86

Current Price：4.99

92.79%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Rocket Pharmaceuticals Inc (RCKT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Rocket Pharmaceuticals Inc (RCKT) has a current Price-to-Book (P/B) ratio of 1.19. Compared to its 3-year average P/B ratio of 3.23, the current P/B ratio is approximately -63.07% higher. Relative to its 5-year average P/B ratio of 3.38, the current P/B ratio is about -64.67% higher. Rocket Pharmaceuticals Inc (RCKT) has a Forward Free Cash Flow (FCF) yield of approximately -54.16%. Compared to its 3-year average FCF yield of -23.87%, the current FCF yield is approximately 126.88% lower. Relative to its 5-year average FCF yield of -18.15%, the current FCF yield is about 198.45% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RCKT competitors is 19751.27, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT.O) exhibits a P/S ratio of 331.93, which is -98.32% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RCKT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RCKT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RCKT currently overvalued or undervalued?

Rocket Pharmaceuticals Inc (RCKT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 331.93 is considered Undervalued compared with the five-year average of -6.90. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 69.21 to 73.86 according to relative valuation method. Compared to the current price of 4.99 USD, Rocket Pharmaceuticals Inc is Undervalued By 92.79%.

What is Rocket Pharmaceuticals Inc (RCKT) fair value?

RCKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 69.21 to 73.86 according to relative valuation method.

How does RCKT's valuation metrics compare to the industry average?

The average P/S ratio for RCKT's competitors is 19751.27, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT) exhibits a P/S ratio of 331.93, which is -98.32% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Rocket Pharmaceuticals Inc (RCKT) as of Mar 02 2026?

As of Mar 02 2026, Rocket Pharmaceuticals Inc (RCKT) has a P/B ratio of 1.19. This indicates that the market values RCKT at 1.19 times its book value.

What is the current FCF Yield for Rocket Pharmaceuticals Inc (RCKT) as of Mar 02 2026?

As of Mar 02 2026, Rocket Pharmaceuticals Inc (RCKT) has a FCF Yield of -54.16%. This means that for every dollar of Rocket Pharmaceuticals Inc's market capitalization, the company generates -54.16 cents in free cash flow.

What is the current Forward P/E ratio for Rocket Pharmaceuticals Inc (RCKT) as of Mar 02 2026?

As of Mar 02 2026, Rocket Pharmaceuticals Inc (RCKT) has a Forward P/E ratio of -2.14. This means the market is willing to pay $-2.14 for every dollar of Rocket Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rocket Pharmaceuticals Inc (RCKT) as of Mar 02 2026?

As of Mar 02 2026, Rocket Pharmaceuticals Inc (RCKT) has a Forward P/S ratio of 331.93. This means the market is valuing RCKT at $331.93 for every dollar of expected revenue over the next 12 months.

RCKT Valuation